Lupin has entered into an agreement with Switzerland-based Sandoz Group AG to market and commercialise its biosimilar ranibizumab in multiple international markets. Under the arrangement, Sandoz will oversee commercialisation in the European Union, excluding Germany, as well as Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will retain responsibility for manufacturing and managing regulatory submissions for these regions.

Sandoz will hold exclusive marketing rights in most of the designated markets, while in France, Australia, Vietnam and Malaysia, rights will be semi-exclusive. In a separate agreement, Sandoz has also secured exclusive rights to commercialise the product in Canada, with Lupin continuing to handle manufacturing and regulatory filings for the Canadian market.

Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Proliferative Diabetic Retinopathy (PDR) and Choroidal Neovascularisation (CNV).

Thierry Volle, President EMEA and Emerging Markets at Lupin, said the collaboration reflects a shared commitment to expanding access to advanced biologic therapies. “We are delighted to partner with Sandoz for the launch and commercialisation of ranibizumab in multiple markets globally. This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients,” he said.